AstraZeneca Malaysia has launched its Evusheld monoclonal antibody combination in local private hospitals for the prevention of Covid-19 in high-risk individuals. In a recent statement, the company said the National Pharmaceutical Regulatory Agency (NPRA) had granted conditional registration for Evusheld in May this year for the pre-exposure prophylaxis (prevention) of Covid-19 in adults and adolescents aged 12 years and older weighing at least 40kg who are unlikely to mount an adequate immune response to Covid-19 vaccination, or for whom Covid-19 vaccination is not recommended.
In a statement on Wednesday (Feb 16), the British-Swedish multinational pharmaceutical and biotechnology company said it has also delivered a further 1,365,200 doses of Covid-19 Vaccine AstraZeneca (ChAdOx1-S [Recombinant]) to Malaysia.
AstraZeneca has delivered an additional 604,100 doses of its Covid-19 vaccine for use in Malaysia to support the country’s ongoing battle against the pandemic. In a statement on Wednesday, AstraZeneca said the latest shipment is part of its bilateral commitment to delivering 6.4 million doses directly to Malaysia.